Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPoolbeg Pharma Regulatory News (POLB)

Share Price Information for Poolbeg Pharma (POLB)

Share Price is delayed by 15 minutes
Get Live Data
8.25    1.10 (14.86%)
Bid:
8.00
Ask:
8.50
Spread: 0.50 (6.25%)
Market Cap: £59.93m
POLB Live PriceLast checked at - London Stock Exchange

Intraday Poolbeg Pharma Share Chart

Form 8.5 Poolbeg Pharma Plc

13 Feb 2025 10:30

RNS Number : 0400X
J & E Davy (UK) Limited
13 February 2025
 

FORM 8.5 (EPT/NON-RI)

 

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY AN

EXEMPT PRINCIPAL TRADER WITHOUT RECOGNISED INTERMEDIARY ("RI") STATUS (OR WHERE RI STATUS IS NOT APPLICABLE)

Rule 8.5 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Name of exempt principal trader:

J&E Davy (UK) Limited

(b) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Poolbeg Pharma PLC

(c) Name of the party to the offer with which exempt principal trader is connected:

Poolbeg Pharma PLC

(d) Date position held/dealing undertaken:

For an opening position disclosure, state the latest practicable date prior to the disclosure

12/02/2025

(e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state "N/A"

N/A

 

2. POSITIONS OF THE EXEMPT PRINCIPAL TRADER

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

 

Class of relevant security:

 

Poolbeg Pharma PLC Ordinary 0.02p

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

169,176

0.03

NA

NA

(2) Cash-settled derivatives:

 

N/A

N/A

N/A

N/A

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

N/A

N/A

N/A

N/A

 

169,176

0.03

NA

NA

 

All interests and all short positions should be disclosed.

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

(b) Rights to subscribe for new securities (including directors' and other employee options)

 

Class of relevant security in relation to which subscription right exists:

N/A

Details, including nature of the rights concerned and relevant percentages:

N/A

 

 

3. DEALINGS (IF ANY) BY THE EXEMPT PRINCIPAL TRADER

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

The currency of all prices and other monetary amounts should be stated.

 

(a) Purchases and sales

 

Class of relevant security

Purchases/ sales

 

Total number of securities

Highest price per unit paid/received

Lowest price per unit paid/received

Poolbeg Pharma PLC Ordinary 0.02p

 

Purchase

143,914

5.05 GBX

5.00 GBX

Poolbeg Pharma PLC Ordinary 0.02p

 

Sale

-

-

-

 

 

(b) Cash-settled derivative transactions

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

N/A

N/A

 

N/A

N/A

N/A

 

(c) Stock-settled derivative transactions (including options)

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

 

(ii) Exercise

 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

N/A

N/A

N/A

N/A

N/A

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

N/A

N/A

N/A

N/A

 

 

4. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

 

None

 

(c) Attachments

 

Is a Supplemental Form 8 (Open Positions) attached?

NO

 

 

Date of disclosure:

13/02/2025

Contact name:

Zaid Ahmad

Telephone number:

016142867

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
FEOBGGDDIDBDGUX
Date   Source Headline
26th May 20227:00 amRNSUS patents granted for POLB 001 and POLB 002
25th May 20224:40 pmRNSSecond Price Monitoring Extn
25th May 20224:35 pmRNSPrice Monitoring Extension
23rd May 20221:01 pmRNSTR-1: Notification of major interest in shares
12th May 20227:00 amRNSGMP manufacturing contract signed
11th May 20227:00 amRNSAttendance at European Melioidosis Congress
27th Apr 20227:00 amRNSDistribution in Specie update
14th Apr 20227:00 amRNSKey POLB 002 European Patent Granted
11th Apr 20227:00 amRNSDistribution in Specie Shareholders
4th Apr 202212:26 pmRNSResult of AGM
31st Mar 20227:00 amRNSPOLB001 Update - Clinical Trial Agreement Signed
30th Mar 20227:00 amRNSCommencement of trading on US OTCQB market
24th Mar 20227:00 amRNSAI deal signed with CytoReason
9th Mar 20227:00 amRNSNotice of AGM
3rd Mar 20227:00 amRNSFinal Results
28th Feb 20227:00 amRNSNotice of Results
24th Feb 20227:00 amRNSArtificial Intelligence deal with OneThree Biotech
31st Jan 20227:00 amRNSConfirmation of vaccine platform licence execution
17th Jan 20227:00 amRNSExclusive license of RNA-based immunotherapy asset
16th Dec 20217:00 amRNSPoolbeg to develop oral vaccine delivery platform
6th Dec 20217:00 amRNSPoolbeg signs option for new vaccine candidate
25th Nov 20217:00 amRNSScientific Advisory Board Appointment
18th Nov 20217:00 amRNSUpdate on POLB 001 Clinical Development
14th Oct 20219:05 amRNSSecond Price Monitoring Extn
14th Oct 20219:00 amRNSPrice Monitoring Extension
14th Oct 20217:00 amRNSPredictViral Patent Update
7th Oct 20217:00 amRNSRNA sequencing ahead of AI analysis programme
13th Sep 20217:00 amRNSSeptember and October Investor conferences
7th Sep 20217:00 amRNSPOLB001 US Patent Update
23rd Aug 20219:06 amRNSSecond Price Monitoring Extn
23rd Aug 20219:00 amRNSPrice Monitoring Extension
4th Aug 202111:30 amRNSHolding(s) in Company
23rd Jul 20211:26 pmRNSTR-1
19th Jul 20217:00 amRNSAdmission to AIM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.